562 related articles for article (PubMed ID: 15668193)
21. Laboratory evidence of hyperfibrinolysis in association with low plasminogen activator inhibitor type 1 activity.
Agren A; Wiman B; Schulman S
Blood Coagul Fibrinolysis; 2007 Oct; 18(7):657-60. PubMed ID: 17890953
[TBL] [Abstract][Full Text] [Related]
22. Effects of direct percutaneous transluminal coronary angioplasty treatment of acute myocardial infarction on plasma levels of haemostatic and fibrinolytic factors.
Saito M; Nakabayashi T; Iuchi K; Ishikawa T; Kaseno K; Yoshida T; Asakura H; Matsuda T
Blood Coagul Fibrinolysis; 1993 Oct; 4(5):801-4. PubMed ID: 7507363
[TBL] [Abstract][Full Text] [Related]
23. A comparative study of the promotion of tissue plasminogen activator and pro-urokinase-induced plasminogen activation by fragments D and E-2 of fibrin.
Liu JN; Gurewich V
J Clin Invest; 1991 Dec; 88(6):2012-7. PubMed ID: 1836471
[TBL] [Abstract][Full Text] [Related]
24. Dyslipidemias and fibrinolysis.
Puccetti L; Bruni F; Pasqui AL; Pastorelli M; Bova G; Cercignani M; Palazzuoli A; Auteri A
Ital Heart J; 2002 Oct; 3(10):579-86. PubMed ID: 12478815
[TBL] [Abstract][Full Text] [Related]
25. [Plasmin-alpha 2-antiplasmin complexes in blood of patient with lichen planus against the background of other fibrinolysis parameters].
Wankiewicz A; Iwan-Zietek I; Kotschy M; Zwolska A
Pol Merkur Lekarski; 2003 Jul; 15(85):72-4. PubMed ID: 14593965
[TBL] [Abstract][Full Text] [Related]
26. Plasminogen activator inhibitor type-1 determines plasmin formation in patients with ischaemic heart disease.
Pedersen OD; Gram J; Jespersen J
Thromb Haemost; 1995 May; 73(5):835-40. PubMed ID: 7482412
[TBL] [Abstract][Full Text] [Related]
27. Protection of single-chain urokinase-type plasminogen activator (scu-PA) in aprotinin treated cardiac surgical patients undergoing cardiopulmonary bypass.
Spannagl M; Dooijewaard G; Dietrich W; Kluft C
Thromb Haemost; 1995 May; 73(5):825-8. PubMed ID: 7482410
[TBL] [Abstract][Full Text] [Related]
28. Tissue plasminogen activator (tPA) inhibits plasmin degradation of fibrin. A mechanism that slows tPA-mediated fibrinolysis but does not require alpha 2-antiplasmin or leakage of intrinsic plasminogen.
Wu JH; Diamond SL
J Clin Invest; 1995 Jun; 95(6):2483-90. PubMed ID: 7769094
[TBL] [Abstract][Full Text] [Related]
29. Fibrinolysis in health and disease: severe abnormalities in systemic lupus erythematosus.
Glas-Greenwalt P; Kant KS; Allen C; Pollak VE
J Lab Clin Med; 1984 Dec; 104(6):962-76. PubMed ID: 6239000
[TBL] [Abstract][Full Text] [Related]
30. The effects of aprotinin and tranexamic acid on thrombin generation and fibrinolytic response after cardiac surgery.
Kuitunen A; Hiippala S; Vahtera E; Rasi V; Salmenperä M
Acta Anaesthesiol Scand; 2005 Oct; 49(9):1272-9. PubMed ID: 16146463
[TBL] [Abstract][Full Text] [Related]
31. Fluorogenic fibrinogen and fibrin facilitate macromolecular assembly and dynamic assay of picomolar levels of plasminogen activators under well mixed conditions.
Wu JH; Diamond SL
Thromb Haemost; 1995 Aug; 74(2):711-7. PubMed ID: 8585011
[TBL] [Abstract][Full Text] [Related]
32. Complete inhibition of fibrinolysis by sustained carboxypeptidase B activity: the role and requirement of plasmin inhibitors.
Walker JB; Bajzar L
J Thromb Haemost; 2007 Jun; 5(6):1257-64. PubMed ID: 17389009
[TBL] [Abstract][Full Text] [Related]
33. Is reduced systemic heparinization justified with heparin-bonded bypass circuits in cardiac surgery?--Experience with and without aprotinin.
Kipfer B; Englberger L; Gygax E; Nydegger U; Carrel T
Transfus Apher Sci; 2003 Aug; 29(1):17-24. PubMed ID: 12877888
[TBL] [Abstract][Full Text] [Related]
34. Angiotensin-converting enzyme inhibition alters the fibrinolytic response to cardiopulmonary bypass.
Pretorius M; Murphey LJ; McFarlane JA; Vaughan DE; Brown NJ
Circulation; 2003 Dec; 108(25):3079-83. PubMed ID: 14656921
[TBL] [Abstract][Full Text] [Related]
35. An alternative pathway for fibrinolysis is activated in patients who have undergone cardiopulmonary bypass surgery and major abdominal surgery.
Gando S; Kameue T; Sawamura A; Hayakawa M; Hoshino H; Kubota N
Thromb Res; 2007; 120(1):87-93. PubMed ID: 17023030
[TBL] [Abstract][Full Text] [Related]
36. Activation of the fibrinolytic system and utilization of the coagulation inhibitors in sepsis: comparison with severe sepsis and septic shock.
Mavrommatis AC; Theodoridis T; Economou M; Kotanidou A; El Ali M; Christopoulou-Kokkinou V; Zakynthinos SG
Intensive Care Med; 2001 Dec; 27(12):1853-9. PubMed ID: 11797019
[TBL] [Abstract][Full Text] [Related]
37. Plasminogen activation in vivo upon intravenous infusion of DDAVP. Quantitative assessment of plasmin-alpha 2-antiplasmin complex with a novel monoclonal antibody based radioimmunoassay.
Levi M; de Boer JP; Roem D; ten Cate JW; Hack CE
Thromb Haemost; 1992 Jan; 67(1):111-6. PubMed ID: 1377412
[TBL] [Abstract][Full Text] [Related]
38. High plasma fibrinogen level is associated with poor clinical outcome in DIC patients.
Wada H; Mori Y; Okabayashi K; Gabazza EC; Kushiya F; Watanabe M; Nishikawa M; Shiku H; Nobori T
Am J Hematol; 2003 Jan; 72(1):1-7. PubMed ID: 12508260
[TBL] [Abstract][Full Text] [Related]
39. Studies on the mechanisms of action of aprotinin and tranexamic acid as plasmin inhibitors and antifibrinolytic agents.
Longstaff C
Blood Coagul Fibrinolysis; 1994 Aug; 5(4):537-42. PubMed ID: 7531000
[TBL] [Abstract][Full Text] [Related]
40. Effect of low-dose aprotinin on coagulation and fibrinolysis in cardiopulmonary bypass.
Kawasuji M; Ueyama K; Sakakibara N; Tedoriya T; Matsunaga Y; Misaki T; Watanabe Y
Ann Thorac Surg; 1993 May; 55(5):1205-9. PubMed ID: 7684219
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
